Physician profile
Muhammad M Haque
NPI 1225103583
$1,017.46
in general payments reported to CMS, 2019-2025
14 companies · $97.74 in 2025
The $97.74 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $79.16 · 2021: $102 · 2022: $17.20 · 2023: $184 · 2024: $118 · 2025: $97.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $248.83 | 2019-2024 | |
| Novo Nordisk INC | $191.95 | 2021-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $167.60 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.01 | 2019 | |
| Abbvie INC. | $96.55 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.71 | 2020 | |
| Allergan, INC. | $22.91 | 2020 | |
| Lilly USA, LLC | $22.70 | 2024 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $22.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.66 | 2019 | |
| Glaxosmithkline, LLC. | $20.54 | 2020 | |
| Amgen INC. | $14.54 | 2025 | Otezla, Repatha |
| Sanofi Pasteur INC. | $14.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.